Clinical characteristics and treatment outcomes of patients with Brugada syndrome in northeastern Thailand

Share this Article

Singapore Med J2014; 55(4): 217-220; http://dx.doi.org/10.11622/smedj.2014055

Makarawate P, Chaosuwannakit N, Vannaprasaht S, Tassaneeyakul W, Sawanyawisuth K
Correspondence: Dr Kittisak Sawanyawisuth, kittisak@kku.ac.th

ABSTRACT
INTRODUCTION Brugada syndrome (BrS) is a common genetic cause of sudden cardiac arrest (SCA) due to polymorphic ventricular tachycardia and ventricular fibrillation. The current recommended therapy for high-risk BrS patients is the use of an implantable cardioverter defibrillator (ICD). The present study aimed to report the clinical characteristics and treatment outcomes of BrS patients in northeastern Thailand.
METHODS Patients who were diagnosed with BrS or had a Brugada electrocardiogram (ECG) between 2005 and 2012 at Khon Kaen University’s hospitals were enrolled in the present study. Patients’ clinical characteristics, ECG type, laboratory results and treatment were reviewed.
RESULTS A total of 90 eligible patients were enrolled. Of these, 79 (87.8%) patients were symptomatic – 65 (82.3%) had documented SCA and 14 (17.7%) had unexplained syncope. The remaining 11 (12.2%) patients were asymptomatic with Brugada ECG. A majority of the patients enrolled were born in northeastern Thailand. The mean age of the symptomatic patients was 44.49 ± 8.55 years. Among the symptomatic patients, a majority were male (n = 77, 97.5%) and 23 (29.1%) patients had a family history of SCA. Almost all BrS patients who were symptomatic (96.2%) received ICD treatment for secondary prevention. The number of patients who received appropriate ICD therapy was 4.2 times of those who received inappropriate shocks. Only 3 (3.8%) symptomatic BrS patients refused ICD treatment.
CONCLUSION Clinical characteristics did not distinguish between symptomatic BrS patients and asymptomatic patients with Brugada ECGs. The clinical characteristics and treatment outcomes for the symptomatic BrS patients with SCA and unexplained syncope were similar. Among the BrS patients implanted with secondary prevention ICD in Northeastern Thailand, nearly one-third had received appropriate ICD therapy, far exceeding the incidence of device-related complications and inappropriate therapy.

Keywords: Brugada syndrome, implantable cardioverter defibrillator, outcomes, treatment
Singapore Med J2014; 55(4): 217-220; http://dx.doi.org/10.11622/smedj.2014055

REFERENCES

1. Tatsanavivat P, Chirawatkul A, Klungboonkrong V, et al. Sudden and unexplained deaths in sleep (Laitai) of young men in rural northeastern Thailand. Int J Epidemiol 1992; 21:904-10. http://dx.doi.org/10.1093/ije/21.5.904

2. Sung RJ, Kuo CT, Wu SN, et al. Sudden cardiac death syndrome: age, gender, ethnicity and genetics. Acta Cardiol Sin 2008; 24:65-74.

3. Nademanee K, Veerakul K, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96:2595-600. http://dx.doi.org/10.1161/01.CIR.96.8.2595

4. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol 1999; 33:5-15. http://dx.doi.org/10.1016/S0735-1097(98)00528-2

5. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, et al. Right ventricular electrocardiographic leads for detection of Brugada syndrome in sudden unexplained death syndrome survivors and their relatives. Clin Cardiol 2001; 24:776-81. http://dx.doi.org/10.1002/clc.4960241205

6. Makarawate P, Sangwatanaroj S. Effect of high glycemic index diets on ST segment elevation in Brugada syndrome. Asean Heart J 2008; 15:57-62.

7. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, et al. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 2001; 22:2290-6. http://dx.doi.org/10.1053/euhj.2001.2691

8. Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003; 107:2221-6. http://dx.doi.org/10.1161/01.CIR.0000066319.56234.C8

9. Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac disease associated with cardiac arrhythmias and sudden death. J Electrocardiol 2000; 33 suppl 1:41-7. http://dx.doi.org/10.1054/jelc.2000.20322

10. Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol 2006; 29:1130 -59. http://dx.doi.org/10.1111/j.1540-8159.2006.00507.x

11. Brugada P, Benito B, Brugada R, Brugada J. Brugada syndrome: update 2009. Hellenic J Cardiol 2009; 50:352-72.

12. Berne P, Brugada J. Brugada syndrome 2012. Circulation 2012; 76:1563-71. http://dx.doi.org/10.1253/circj.CJ-12-0717

13. Sarkozy A, Sorgente A, Boussy T, et al. The value of family history of sudden death in patients with diagnosis type 1 Brugada ECG pattern. Eur Heart J 2011; 32:2153-60. http://dx.doi.org/10.1093/eurheartj/ehr129

14. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006; 114:2317-24. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.628537